JP2018502141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502141A5 JP2018502141A5 JP2017537966A JP2017537966A JP2018502141A5 JP 2018502141 A5 JP2018502141 A5 JP 2018502141A5 JP 2017537966 A JP2017537966 A JP 2017537966A JP 2017537966 A JP2017537966 A JP 2017537966A JP 2018502141 A5 JP2018502141 A5 JP 2018502141A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- branched
- linear
- occurrence
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001931 aliphatic group Chemical group 0.000 claims description 241
- 229910052760 oxygen Inorganic materials 0.000 claims description 125
- 229910052739 hydrogen Inorganic materials 0.000 claims description 110
- 229910052717 sulfur Inorganic materials 0.000 claims description 110
- 229910052757 nitrogen Inorganic materials 0.000 claims description 91
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 91
- 239000001257 hydrogen Substances 0.000 claims description 88
- 125000005842 heteroatom Chemical group 0.000 claims description 71
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 69
- 239000001301 oxygen Chemical group 0.000 claims description 69
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 65
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 65
- 239000011593 sulfur Chemical group 0.000 claims description 58
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 53
- 229910052736 halogen Inorganic materials 0.000 claims description 48
- 150000002367 halogens Chemical group 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 35
- 125000004429 atom Chemical group 0.000 claims description 29
- 125000002947 alkylene group Chemical group 0.000 claims description 26
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 13
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 12
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 11
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 claims description 8
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 claims description 8
- -1 cycloaliphatic Chemical group 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 150000001412 amines Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003464 sulfur compounds Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105387P | 2015-01-20 | 2015-01-20 | |
| US62/105,387 | 2015-01-20 | ||
| PCT/US2016/014026 WO2016118565A1 (en) | 2015-01-20 | 2016-01-20 | Quinazoline and quinoline compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018502141A JP2018502141A (ja) | 2018-01-25 |
| JP2018502141A5 true JP2018502141A5 (https=) | 2019-02-28 |
Family
ID=56417670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017537966A Pending JP2018502141A (ja) | 2015-01-20 | 2016-01-20 | キナゾリン及びキノリン化合物、ならびにその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10323018B2 (https=) |
| EP (1) | EP3247705B1 (https=) |
| JP (1) | JP2018502141A (https=) |
| CN (1) | CN107438598A (https=) |
| CA (1) | CA2974078A1 (https=) |
| WO (1) | WO2016118565A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3039589A1 (en) | 2016-10-18 | 2018-04-26 | Seattle Genetics, Inc. | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors |
| CN108976173B (zh) * | 2016-12-30 | 2022-01-18 | 江西师范大学 | 一种4-芳基-2-(2-(硫三氟甲基)芳基)喹唑啉的制备方法 |
| CA3060206A1 (en) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| CN108929267B (zh) * | 2018-07-09 | 2021-07-02 | 中南大学 | 一种喹诺酮骨架及其合成方法 |
| KR20210108367A (ko) * | 2018-11-09 | 2021-09-02 | 비바체 테라퓨틱스, 인크. | 비시클릭 화합물 |
| MX2021012638A (es) | 2019-04-16 | 2022-01-04 | Vivace Therapeutics Inc | Compuestos biciclicos. |
| US20230098872A1 (en) * | 2021-03-26 | 2023-03-30 | Cedilla Therapeutics, Inc. | Tead inhibitors and uses thereof |
| WO2024233563A1 (en) * | 2023-05-09 | 2024-11-14 | Amgen Inc. | 6,6-fused bicyclic amides and compositions for use as 15-prostaglandin dehydrogenase modulators |
| WO2025168575A1 (en) | 2024-02-05 | 2025-08-14 | Institut National de la Santé et de la Recherche Médicale | Inhibitors of nad biosynthesis for the treatment of dengue virus infections |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999042461A1 (en) | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
| AR043059A1 (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| US7189724B2 (en) * | 2003-04-15 | 2007-03-13 | Valeant Research And Development | Quinoxaline derivatives having antiviral activity |
| WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
| JP2007099641A (ja) | 2005-09-30 | 2007-04-19 | Tsumura & Co | インドールキノキサリン類化合物、その製造方法およびそれを用いた医薬組成物 |
| US8119656B2 (en) | 2007-12-07 | 2012-02-21 | The Board Of Regents Of The University Of Texas System | Inhibitors of the influenza virus non-structural 1 protein |
| CA2729757A1 (en) * | 2008-07-01 | 2010-01-07 | The Johns Hopkins University | Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase |
| RU2011111728A (ru) | 2008-08-29 | 2012-10-10 | Топотаргет А/С (Dk) | Новые производные мочевины и тиомочевины |
| CA2764694A1 (en) | 2009-06-09 | 2010-12-16 | Topotarget A/S | Pyridinyl derivatives asinhibitors of enzyme nicotinamide phosphoribosyltransferase |
| AU2010289397B2 (en) | 2009-09-03 | 2016-05-26 | Bioenergenix | Heterocyclic compounds for the inhibition of PASK |
| US20130317027A1 (en) | 2010-03-01 | 2013-11-28 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| AU2011223790A1 (en) | 2010-03-01 | 2012-08-30 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
| EP2552444B1 (en) | 2010-04-01 | 2018-10-10 | Council of Scientific & Industrial Research | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY |
| TWI516264B (zh) | 2010-05-06 | 2016-01-11 | 臺北醫學大學 | 芳香醯喹啉化合物 |
| EP2611804A1 (en) | 2010-09-03 | 2013-07-10 | Forma TM, LLC. | Novel compounds and compositions for the inhibition of nampt |
| AR082886A1 (es) | 2010-09-03 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones farmaceuticas que los contienen |
| CN103270023B (zh) | 2010-09-03 | 2016-11-02 | 福马Tm有限责任公司 | 作为用于治疗疾病诸如癌症的nampt 抑制剂的4-{[(吡啶-3-基-甲基)氨基羰基]氨基}苯-砜衍生物 |
| MX2013005479A (es) | 2010-11-15 | 2013-06-12 | Abbvie Inc | Inhibidores de nampt. |
| US9469615B2 (en) | 2010-12-23 | 2016-10-18 | Merck Sharp & Dohme Corp. | Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators |
| WO2012094462A2 (en) | 2011-01-05 | 2012-07-12 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| US20120225846A1 (en) | 2011-03-02 | 2012-09-06 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| WO2012119046A2 (en) | 2011-03-02 | 2012-09-07 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| US10953012B2 (en) | 2011-04-26 | 2021-03-23 | Bioenergenix Llc | Heterocyclic compounds for the inhibition of pask |
| RU2616612C2 (ru) | 2011-05-04 | 2017-04-18 | ФОРМА ТиЭм, ЭлЭлСИ | Новые соединения и композиции для ингибирования nampt |
| MX347459B (es) * | 2011-05-09 | 2017-04-26 | Forma Tm Llc | Nuevos compuestos y composiciones para la inhibición de nampt. |
| WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2739144A4 (en) | 2011-06-20 | 2015-04-01 | Alzheimer S Inst Of America Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
| JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
| CA2855510A1 (en) | 2011-11-11 | 2013-05-16 | Abbvie Inc. | Nampt inhibitors |
| WO2013082150A1 (en) | 2011-11-30 | 2013-06-06 | The Curators Of The University Of Missouri | Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt) |
| WO2013130935A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Amido-benzyl sulfoxide derivatives |
| WO2013130943A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Alkyl-and di-substituted amido-benzyl sulfonamide derivatives |
| JP2015508785A (ja) | 2012-03-02 | 2015-03-23 | ジェネンテック， インコーポレイテッド | ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体 |
| WO2013127268A1 (en) | 2012-03-02 | 2013-09-06 | Genentech,Inc. | Amido-benzyl sulfone and sulfonamide derivatives |
| TW201343645A (zh) | 2012-03-30 | 2013-11-01 | Cubist Pharm Inc | １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑 |
| DK2838533T3 (da) | 2012-04-16 | 2017-11-27 | Univ Case Western Reserve | Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet |
| AR091023A1 (es) | 2012-05-11 | 2014-12-30 | Abbvie Inc | Inhibidores del nampt |
| MX2014013758A (es) | 2012-05-11 | 2015-02-05 | Abbvie Inc | Derivados de tiazolcarboxamida para usarse como inhibidores de nampt. |
| WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
| CN104684906B (zh) | 2012-05-11 | 2017-06-09 | 艾伯维公司 | Nampt抑制剂 |
| PE20150224A1 (es) | 2012-05-11 | 2015-03-08 | Abbvie Inc | Inhibidores del nampt |
| JP2015522028A (ja) | 2012-06-27 | 2015-08-03 | アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッドＡｌｚｈｅｉｍｅｒ’Ｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ａｍｅｒｉｃａ， Ｉｎｃ． | 化合物とその治療用途 |
| GEAP201814220A (en) | 2013-12-24 | 2018-03-12 | Oncotartis Inc | Benzamide and nicotinamide compounds and methods of using same |
| CN106458934B (zh) | 2014-04-18 | 2019-08-16 | 米伦纽姆医药公司 | 喹喔啉化合物及其用途 |
-
2016
- 2016-01-20 CA CA2974078A patent/CA2974078A1/en not_active Abandoned
- 2016-01-20 JP JP2017537966A patent/JP2018502141A/ja active Pending
- 2016-01-20 CN CN201680013053.4A patent/CN107438598A/zh active Pending
- 2016-01-20 WO PCT/US2016/014026 patent/WO2016118565A1/en not_active Ceased
- 2016-01-20 EP EP16740634.7A patent/EP3247705B1/en active Active
- 2016-01-20 US US15/544,192 patent/US10323018B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502141A5 (https=) | ||
| JP2017514809A5 (https=) | ||
| JP2020520955A5 (https=) | ||
| RU2019142472A (ru) | Глюкуронидные пролекарства ингибиторов янус-киназы | |
| JP2016518437A5 (https=) | ||
| JP2015532295A5 (https=) | ||
| JP2011513305A5 (https=) | ||
| JP2009536620A5 (https=) | ||
| CA2694270A1 (en) | Substituted aryloxazoles and the use thereof | |
| JP2016516699A5 (https=) | ||
| JP2017537940A5 (https=) | ||
| JP2009526830A5 (https=) | ||
| JP2016515561A5 (https=) | ||
| RU2009132188A (ru) | Режим дозирования ингибиторов комт | |
| JP2017502092A5 (https=) | ||
| MX2020011317A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih. | |
| JP2016531126A5 (https=) | ||
| JP2021501756A5 (https=) | ||
| JP2012513390A5 (https=) | ||
| RU2018105614A (ru) | Производное 1,3,5-триазина и способ его применения | |
| JP2018528942A5 (https=) | ||
| RU2017141561A (ru) | Производные тетрагидронафтиридинилпропионовой кислоты и их применение | |
| RU2013141559A (ru) | Способ ингибирования клеток опухоли гамартомы | |
| RU2012109554A (ru) | Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией | |
| RU2013136861A (ru) | Новое производное индола или индазола или его соль |